001     154376
005     20240229112711.0
024 7 _ |a 10.1126/sciadv.aau6732
|2 doi
024 7 _ |a pmid:30788433
|2 pmid
024 7 _ |a pmc:PMC6374104
|2 pmc
024 7 _ |a altmetric:55477710
|2 altmetric
037 _ _ |a DKFZ-2020-00716
041 _ _ |a eng
082 _ _ |a 500
100 1 _ |a Kim, Jaeryung
|0 0000-0002-8003-5849
|b 0
245 _ _ |a Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration.
260 _ _ |a Washington, DC [u.a.]
|c 2019
|b Assoc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1585909833_30668
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a DKFZ-ZMBH Alliance
520 _ _ |a Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade for NV-AMD has shown beneficial outcomes, unmet medical needs for patients refractory or tachyphylactic to anti-VEGF therapy exist. In addition, the treatment could exacerbate choriocapillary rarefaction, necessitating advanced treatment for fundamental recovery from NV-AMD. In this study, Tie2 activation by angiopoietin-2-binding and Tie2-activating antibody (ABTAA) presents a therapeutic strategy for NV-AMD. Conditional Tie2 deletion impeded choriocapillary maintenance, rendering eyes susceptible to NV-AMD development. Moreover, in a NV-AMD mouse model, ABTAA not only suppressed choroidal neovascularization (CNV) and vascular leakage but also regenerated the choriocapillaris and relieved hypoxia. Conversely, VEGF blockade degenerated the choriocapillaris and exacerbated hypoxia, although it suppressed CNV and vascular leakage. Together, we establish that angiopoietin-Tie2 signaling is critical for choriocapillary maintenance and that ABTAA represents an alternative, combinative therapeutic strategy for NV-AMD by alleviating anti-VEGF adverse effects.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Angiopoietin-1
|2 NLM Chemicals
650 _ 7 |a Angpt1 protein, mouse
|2 NLM Chemicals
650 _ 7 |a Vascular Endothelial Growth Factor A
|2 NLM Chemicals
650 _ 7 |a Receptor, TIE-2
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a Tek protein, mouse
|0 EC 2.7.10.1
|2 NLM Chemicals
700 1 _ |a Park, Jang Ryul
|0 0000-0002-5044-3278
|b 1
700 1 _ |a Choi, Jeongwoon
|b 2
700 1 _ |a Park, Intae
|b 3
700 1 _ |a Hwang, Yoonha
|b 4
700 1 _ |a Bae, Hosung
|0 0000-0001-5848-7972
|b 5
700 1 _ |a Kim, Yongjoo
|0 0000-0001-9114-9086
|b 6
700 1 _ |a Choi, WooJhon
|b 7
700 1 _ |a Yang, Jee Myung
|0 0000-0001-5729-2233
|b 8
700 1 _ |a Han, Sangyeul
|0 0000-0002-2762-6340
|b 9
700 1 _ |a Chung, Tae-Young
|b 10
700 1 _ |a Kim, Pilhan
|0 0000-0001-8388-1840
|b 11
700 1 _ |a Kubota, Yoshiaki
|0 0000-0001-6672-4122
|b 12
700 1 _ |a Augustin, Hellmut
|0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
|b 13
|u dkfz
700 1 _ |a Oh, Wang-Yuhl
|b 14
700 1 _ |a Koh, Gou Young
|0 0000-0002-1231-1485
|b 15
773 _ _ |a 10.1126/sciadv.aau6732
|g Vol. 5, no. 2, p. eaau6732 -
|0 PERI:(DE-600)2810933-8
|n 2
|p eaau6732 -
|t Science advances
|v 5
|y 2019
|x 2375-2548
909 C O |o oai:inrepo02.dkfz.de:154376
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI ADV : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC (No Version)
|0 LIC:(DE-HGF)CCBYNCNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b SCI ADV : 2017
920 1 _ |0 I:(DE-He78)A190-20160331
|k A190
|l A190 Vaskuläre Onkologie und Metastatistierung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A190-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21